101. Updates in the management of cranial dural arteriovenous fistula.
- Author
-
Baharvahdat H, Ooi YC, Kim WJ, Mowla A, Coon AL, and Colby GP
- Subjects
- Central Nervous System Vascular Malformations diagnostic imaging, Central Nervous System Vascular Malformations mortality, Central Nervous System Vascular Malformations physiopathology, Cerebrovascular Circulation, Clinical Decision-Making, Humans, Risk Assessment, Risk Factors, Treatment Outcome, Central Nervous System Vascular Malformations therapy, Embolization, Therapeutic adverse effects, Embolization, Therapeutic mortality, Endovascular Procedures adverse effects, Endovascular Procedures mortality, Neurosurgical Procedures adverse effects, Neurosurgical Procedures mortality, Radiosurgery adverse effects, Radiosurgery mortality
- Abstract
Dural arteriovenous fistula (dAVF) accounts for approximately 10% of all intracranial vascular malformations. While they can be benign lesions, the presence of retrograde venous drainage and cortical venous reflux makes the natural course of these lesions aggressive high risk of haemorrhage, neurological injury and mortality. Endovascular treatment is often the first line of treatment for dAVF. Both transarterial and transvenous approaches are used to cure dAVF. The selection of treatment approach depends on the angioarchitecture of the dAVF, the location, the direction of venous flow. Surgery and, to a lesser extent, stereotactic radiosurgery are used when endovascular approaches are impossible or unsuccessful., Competing Interests: Competing interests: GPC is a consultant for Medtronic, Stryker and MicroVention. ALC is a consultant for Medtronic, Stryker, MicroVention and InNeuroCo., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF